- Shidlovski / Getty Images
- Three drugmakers are being accused in a large federal lawsuit of working together to hike the price of a decades-old generic antifungal medication.
- The complaint alleges that rival companies shared information about price increases by way of phone calls and text messages, resulting in the drug’s price doubling.
- Communications between employees are included as part of allegations in a large civil antitrust complaint being brought by attorneys general for most US states against nearly 20 generic drugmakers.
- Also read: A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside story.
It wasn’t a coincidence when several drugmakers all began to increase the price of a decades-old generic drug in 2014, according to newly revealed allegations in a massive federal lawsuit.
The drug, nystatin, was made by at least three generic drugmakers, all of which had employees in close, cozy contact about the ensuing price hike, according to the complaint. Forms of nystatin are used to treat common fungal infections such as yeast infections and diaper rash.
The group of attorneys general allege that, while on a call about the medicine, one employee working for the New Jersey drugmaker Heritage Pharmaceuticals sent the following text message to an employee of a rival company.
“Work news: we are raising price on Nystatin. Just letting you know. :),” the employee said.
The attorneys general claim that the competitor, Indian drugmaker Sun Pharmaceuticals, then also started increasing the price of its nystatin.
A Sun representative said the company believed the allegations were meritless and that it would continue to defend itself “vigorously.”
- Shayanne Gal / BI Graphics
Attorneys general for 45 states, plus the District of Columbia and Puerto Rico, allege that nearly 20 companies that manufacture generic drugs, including Sun, illegally collaborated with competitors to jack up prices for pharmaceuticals and divvy up markets to limit competition.
AGs claim rival drugmakers communicated about how to raise price
Business Insider is the first to report on the unredacted suit, which alleges specific communications between employees of rival drugmakers about how to increase prices.
Other medications outlined in the complaint treat conditions like epilepsy, heart failure, anxiety, insomnia, hypertension, diabetes, asthma, and arthritis.
The AGs claim that conversations between two nystatin manufacturers, Teva, an Israeli company that is the world’s largest generic drugmaker, and Heritage, dated back to mid-2013.
They allege increases had been broached internally at Teva first, but the Teva employee who headed the generics company’s pricing team initially opposed them.
And they claim that, after conversations with a high-ranking Heritage leader, the Teva employee later added the drug to a list of “price increase candidates.”
The complaint alleges that the decision dragged into 2014, when the drug was again on a spreadsheet of price-increase candidates, with the note that the decision had been shared with its two main nystatin rivals.
AGs allege the drug’s price doubled to about $100
Teva then doubled the drug’s price, to roughly $100, the complaint says.
Teva said in a statement that it denied the allegations and “will continue to vigorously defend itself.”
In a statement to Business Insider, Heritage said that it fired its former president and CEO in 2016 after an internal investigation revealed “serious misconduct” and has been cooperating with an ongoing federal criminal investigation into suspicions of price-fixing, bid-rigging, and other anticompetitive conduct in the generic-drug industry. The company is also suing the former executives in a separate ongoing suit, the statement added.
“We are deeply disappointed by the misconduct and are committed to ensuring it does not happen again,” the statement said.
Lawyers for the former executives, Jason Malek and Jeffrey Glazer, told Business Insider in a statement that the Heritage lawsuit “is malicious and without merit, and we look forward to demonstrating this in court.”